TIDMFAB

RNS Number : 6444H

Fusion Antibodies PLC

19 November 2018

Fusion Antibodies plc

("Fusion" or the "Company")

Notice of Results

Fusion Antibodies plc (AIM: FAB), a contract research organisation providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications, announces it will release its interim results for the six months ended 30 September 2018 on Monday, 26 November 2018.

Enquiries:

 
 Fusion Antibodies plc                                     www.fusionantibodies.com 
 Dr Paul Kerr, Chief Executive Officer                              Via Walbrook PR 
 James Fair, Chief Financial Officer 
 
 Allenby Capital Limited                                   Tel: +44 (0)20 3328 5656 
 Virginia Bull / James Reeve / Asha Chotai 
 
 Walbrook PR                      Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com 
 Anna Dunphy                                               Mob: +44 (0)7876 740 001 
 Paul McManus                                              Mob: +44 (0)7980 541 983

About Fusion Antibodies plc

Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx(TM) platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced over 250 antibodies and successfully completed over 100 humanisation projects for its international, blue-chip client base, which includes eight of the top 10 global pharmaceutical companies by revenue.

The Company was established in 2001 as a spin out from Queen's University Belfast. It was initially a drug development business but revised its operations to focus on CRO work in 2011. The Company has a highly experienced management team with a combined 47 years' experience in the biopharma industry.

The global monoclonal antibody therapeutics market, which accounted for 43 per cent. of the global biologics market in 2016, was valued at between $85.4 billion and $86.7 billion in 2015 and is forecast to increase at a CAGR of between 8.2 per cent. and 12.2 per cent. for the period 2016 to 2024.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NORLLFVFLSLRLIT

(END) Dow Jones Newswires

November 19, 2018 02:00 ET (07:00 GMT)

Fusion Antibodies (LSE:FAB)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Fusion Antibodies Charts.
Fusion Antibodies (LSE:FAB)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Fusion Antibodies Charts.